University of Oxford-Novavax Malaria Vaccine Demonstrates 77% Efficacy in Children

Malaria has been an extraordinarily difficult challenge for vaccine development because of the three orders of magnitude larger number of genes present compared to a virus. Malaria is a protozoa. Jenner and Novavax were working on this vaccine several years prior to the pandemic and claim the knowledge gained in this pursuit accelerated development of their COVID-19 vaccine. This vaccine is a protein vaccine and not an adenovirus vector. The antigen is a malaria circumsporozoite protein attached to a hepatitis B surface protein of all things. We'll be needing this in the northern climates before long thanks to the major climate shifts unfolding.